Literature DB >> 30980261

Vascular syndromes in liver cirrhosis.

Botros Shenoda1, Joseph Boselli2,3.   

Abstract

Liver cirrhosis is associated with multiple vascular syndromes affecting almost all body systems. Many of these syndromes are directly related to impaired liver function and sometimes reversible after liver transplantation while others arise secondary to portal hypertension and ascites. Altered expression of angiogenic and vasoactive compounds (most importantly nitric oxide), endothelial dysfunction, dysregulated neurohormonal control, and systemic inflammatory state play differential roles in mediating homeostatic instability and abnormal vasogenic response. Important vascular features encountered in liver disease include portal hypertension, splanchnic overflow, abnormal angiogenesis and shunts, portopulmonary syndrome, hepatopulmonary syndrome, and systemic hyperdynamic circulation. Redistribution of effective circulatory volume deviating from vital organs and pooling in splanchnic circulation is also encountered in liver patients which may lead to devastating outcomes as hepatorenal syndrome. Etiologically, vascular syndromes are not isolated phenomena and vascular dysfunction in one system may lead to the development of another in a different system. This review focuses on understanding the pathophysiological factors underlying vascular syndromes related to chronic liver disease and the potential links among them. Many of these syndromes are associated with high mortality, thus it is crucial to look for early biomarkers for these syndromes and develop novel preventive and therapeutic strategies.

Entities:  

Keywords:  Hepatopulmonary syndrome; Hepatorenal syndrome; Liver cirrhosis; Portal hypertension; Portopulmonary hypertension

Mesh:

Year:  2019        PMID: 30980261     DOI: 10.1007/s12328-019-00956-0

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  6 in total

1.  The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data.

Authors:  David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

2.  Fractional Excretion of Sodium and Urea in Differentiating Acute Kidney Injury Phenotypes in Decompensated Cirrhosis.

Authors:  Yashavanth H S Gowda; Nitin Jagtap; Arun Karyampudi; Nagaraja P Rao; Gujjarapudi Deepika; Mithun Sharma; Rajesh Gupta; Manu Tandan; Mohan Ramchandani; Priyadarshini John; Anand Kulkarni; Pramod Kumar; Bhushan Bhaware; Mohan V Turpati; D Nageshwar Reddy
Journal:  J Clin Exp Hepatol       Date:  2021-09-28

3.  The Presence of Ascites Affects the Predictive Value of HVPG on Early Rebleeding in Patients with Cirrhosis.

Authors:  Chuan Liu; Ruoyang Shao; Sining Wang; Guangchuan Wang; Lifen Wang; Mingyan Zhang; Yanna Liu; Mingkai Liang; Xiaoguo Li; Ning Kang; Jitao Wang; Dan Xu; Hua Mao; Chunqing Zhang; Xiaolong Qi
Journal:  Gastroenterol Res Pract       Date:  2020-11-24       Impact factor: 2.260

4.  Implications of BMP9/10 for patients with liver cirrhosis.

Authors:  Dong Ji; Guofeng Chen; Yongping Yang
Journal:  EBioMedicine       Date:  2020-07-03       Impact factor: 8.143

5.  Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study.

Authors:  Nuria Mendoza; Eva Rivas; Roberto Rodriguez-Roisin; Tamara Garcia; Miquel Bruguera; Alvar Agusti; Rosa Faner
Journal:  PLoS One       Date:  2021-02-25       Impact factor: 3.240

Review 6.  Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.

Authors:  Takuya Adachi; Yasuto Takeuchi; Akinobu Takaki; Atsushi Oyama; Nozomu Wada; Hideki Onishi; Hidenori Shiraha; Hiroyuki Okada
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.